Proteins mediating collagen biosynthesis and accumulation in arterial repair: Novel targets for anti-restenosis therapy

Cardiovascular Research

Volumn 91, Issue 1, 2011, Pages 16-26

  Osherov, Azriel B ^a   Gotha, Lara ^a   Cheema, Asim N ^b   Qiang, Beiping ^a   Strauss, Bradley H ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Balloon angioplasty and stenting; Collagen synthesis and processing; Extracellular matrix; Extracellular response

Indexed keywords

2 BUTYL 7 [2 (2 CARBOXYPROPYL) 4 METHOXYPHENYL] 5 (3,4 METHYLENEDIOXYPHENYL)CYCLOPENTENO[1,2 B]PYRIDINE 6 CARBOXYLIC ACID; ALDOSTERONE ANTAGONIST; ATRASENTAN; BATIMASTAT; COLLAGEN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYTOKINE; DECORIN; ENDOTHELIN RECEPTOR ANTAGONIST; GROWTH FACTOR; IMATINIB; INTEGRIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PIOGLITAZONE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEOGLYCAN; RO 1132908; TRANILAST; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG;

ARTERY RECONSTRUCTION; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; EXTRACELLULAR MATRIX; GENE TARGETING; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; CARDIOVASCULAR AGENTS; COLLAGEN; COLLAGENASES; CORONARY RESTENOSIS; CORONARY STENOSIS; CYTOKINES; ENZYME INHIBITORS; HUMANS; INTEGRINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN-LYSINE 6-OXIDASE; SIGNAL TRANSDUCTION; STENTS;

EID: 79958795393     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr012     Document Type: Review

References (145)

1. Kronemann N, Bouloumi A, Bassus S, Kirchmaier CM, Busse R, Schini-Kerth VB. Aggregating human platelets stimulate expression of vascular endothelial growth factor in cultured vascular smooth muscle cells through a synergistic effect of transforming growth factor-beta 1 and platelet derived growth factor AB. Circulation 1999; 100:855-860. (Pubitemid 29398885)
2. Raines EW, Koyama H, Carragher NO. The extracellular matrix dynamically regulates smooth muscle cell responsiveness to PDGF. Ann N Y Acad Sci 2000;902: 39-51.
3. Ichii T, Koyama H, Tanaka S, Kim S, Shioi A, Okuno Y et al. Fibrillar collagen specifically regulates human vascular smooth muscle cell genes involved in cellular responses and the pericellular matrix environment. Circ Res 2001;88:460-467. (Pubitemid 32240908)
4. Strauss BH, Robinson R, Batchelor WB, Chisholm RJ, Ravi G, Natarajan MK et al. In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ Res 1996;79:541-550. (Pubitemid 26276914)
5. Li C, Cantor W, Nili N, Robinson R, Fenkell L, Tran Y et al. Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor. J Am Coll Cardiol 2002;39:1852-1858. (Pubitemid 34595299)
6. Farb A, Kolodgie FD, Hwang JY, Burke AP, Tefera K, Weber DK et al. Extracellular matrix changes in stented human coronary arteries. Circulation 2004;110:940-947. (Pubitemid 39128619)
7. Brasselet C, Durand E, Addad F, Al Haj Zen A, Smeets MB, Laurent-Maquin D et al. Collagen and elastin cross-linking: a mechanism of constrictive remodeling after arterial injury. Am J Physiol Heart Circ Physiol 2005;89:H2228-H2233. (Pubitemid 41507377)
8. Okamoto E, Couse T, De Leon H, Vinten-Johansen J, Goodman RB, Scott NA et al. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation 2001;104:2228-2235. (Pubitemid 33043305)
9. Tanaka H, Sukhova G, Schwartz D, Libby P. Proliferating arterial smooth muscle cells after balloon injury express TNF-alpha but not interleukin-1 or basic fibroblast growth factor. Arterioscler Thromb Vasc Biol 1996;16:12-18. (Pubitemid 26026926)
10. Majesky MW, Reidy MA, Bowen-Pope DF, Hart CE, Wilcox JN, Schwartz SM. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol 1990; 111:2149-2158.
11. Wysocki SJ, Zheng MH, Fan Y, Lamawansa MD, House AK, Norman PE. Expression of transforming growth factor-beta1 (TGF-beta1) and urokinase-type plasminogen activator (u-PA) genes during arterial repair in the pig. Cardiovasc Res 1996;31: 28-36.
12. Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D, Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 1996;94:1655-1664. (Pubitemid 26320272)
13. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983; 49:327-333. (Pubitemid 13012062)
14. Strauss BH, Umans VA, van Suylen RJ, de Feyter PJ, Marco J, Robertson GC et al. Directional atherectomy for treatment of restenosis within coronary stents: clinical, angiographic and histologic results. J Am Coll Cardiol 1992;20:1465-1473. (Pubitemid 23007498)
15. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44-52. (Pubitemid 29035956)
16. Chung IM, Gold HK, Schwartz SM, Ikari Y, Reidy MA, Wight TN. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J Am Coll Cardiol 2002;40:2072-2081. (Pubitemid 36005890)
17. Brooke BS, Karnik SK, Li DY. Extracellular matrix in vascular morphogenesis and disease: structure versus signal. Trends Cell Biol 2003;13:51-56. (Pubitemid 35453895)
18. Shekhonin BV, Domogatsky SP, Muzykantov VR, Idelson GL, Rukosuev VS. Distribution of type I, III, IV and V collagen in normal and atherosclerotic human arterial wall: immunomorphological characteristics. Coll Relat Res 1985;5:355-368. (Pubitemid 15237177)
19. Canty EG, Kadler KE. Procollagen trafficking, processing and fibrillogenesis. J Cell Sci 2005;118:1341-1353. (Pubitemid 40585115)
20. Shoulders MD, Raines RT. Collagen structure and stability. Annu Rev Biochem 2009; 78:929-958.
21. Gorres KL, Raines RT. Prolyl 4-hydroxylase. Crit Rev Biochem Mol Biol 2010;45: 106-124.
22. Nagata K. HSP47 as a collagen-specific molecular chaperone: function and expression in normal mouse development. Semin Cell Dev Biol 2003;14:275-282. (Pubitemid 38160952)
23. López B, González A, Hermida N, Valencia F, de Teresa E, D́ez J. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol 2010;299:H1-H9.
24. Franco CD, Hou G, Bendeck MP. Collagens, integrins, and the discoidin domain receptors in arterial occlusive disease. Trends Cardiovasc Med 2002;12:143-148. (Pubitemid 34586817)
25. White DJ, Puranen S, Johnson MS, Heino J. The collagen receptor subfamily of the integrins. Int J Biochem Cell Biol 2004;36:1405-1410. (Pubitemid 38625821)
26. Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res 2010;339:269-280.
27. Gahmberg CG, Fagerholm SC, Nurmi SM, Chavakis T, Marchesan S, Grönholm M. Regulation of integrin activity and signalling. Biochim Biophys Acta 2009;1790: 431-444.
28. Fields GB. A model for interstitial collagen catabolism by mammalian collagenases. J Theor Biol 1991;153:585-602.
29. Lauer-Fields JL, Juska D, Fields GB. Matrix metalloproteinases and collagen catabolism. Biopolymers 2002;66:19-32.
30. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for the matrix anymore! Curr Opin Cell Biol 2001;13:534-540. (Pubitemid 32817010)
31. Kerkvliet EH, Docherty AJ, Beertsen W, Everts V. Collagen breakdown in soft connective tissue explants is associated with the level of active gelatinase A (MMP-2) but not with collagenase. Matrix Biol 1999;18:373-380. (Pubitemid 29397449)
32. Atkinson SJ, Patterson ML, Butler MJ, Murphy G. Membrane type 1 matrix metalloproteinase and gelatinase A synergistically degrade type 1 collagen in a cell model. FEBS Lett 2001;491:222-226. (Pubitemid 32193800)
33. d'Ortho MP, Will H, Atkinson S, Butler G, Messent A, Gavrilovic J et al. Membranetype matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 1997;250: 751-757. (Pubitemid 28022492)
34. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89:201-210. (Pubitemid 34132679)
35. Salter RC, Ashlin TG, Kwan AP, Ramji DP. ADAMTS proteases: key roles in atherosclerosis? J Mol Med 2010 Jul 22. [Epub ahead of print].
36. Jönsson-Rylander A, Nilsson T, Fritsche-Danielson R, Hammarström A, Behrendt M, Andersson J et al. Role of ADAMTS-1 in atherosclerosis: Remodeling of carotid artery, immunohistochemistry, and proteolysis of Versican. Arterioscler Thromb Vasc Biol 2005;25:180-185. (Pubitemid 40054273)
37. Wang L, Zheng J, Bai X, Liu B, Liu C, Xu Q et al. ADAMTS-7 mediates vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries. Circ Res 2009;104:688-698.
38. Tortorella MD, Tomasselli AG, Mathis KJ, Schnute ME, Woodard SS, Munie G et al. Structural and inhibition analysis reveals the mechanism of selectivity of a series of aggrecanase inhibitors. J Biol Chem 2009;284:24185-24191.
39. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF,Wong C et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996;94:35-43. (Pubitemid 126426397)
40. Kingston PA, Sinha S, David A, Castro MG, Lowenstein PR, Heagerty AM. Adenovirus-mediated gene transfer of a secreted transforming growth factor-beta Type II receptor inhibits luminal loss and constrictive remodeling after coronary angioplasty and enhances adventitial collagen deposition. Circulation 2001;104: 2595-2601. (Pubitemid 33104799)
41. Coats WD Jr, Whittaker P, Cheung DT, Currier JW, Han B, Faxon DP. Collagen content is significantly lower in restenotic versus nonrestenotic vessels after balloon angioplasty in the atherosclerotic rabbit model. Circulation 1997;95: 1293-1300. (Pubitemid 27097843)
42. Lafont A, Durand E, Samuel JL, Besse B, Addad F, Levy BI et al. Endothelial dysfunction and collagen accumulation: two independent factors for restenosis and constrictive remodeling after experimental angioplasty. Circulation 1999;100:1109-1115. (Pubitemid 29416238)
43. Schmidt MR, Maeng M, Kristiansen SB, Andersen HR, Falk E. The natural history of collagen and alpha-actin expression after coronary angioplasty. Cardiovasc Pathol 2004;13:260-267. (Pubitemid 39195210)
44. Sierevogel MJ, Velema E, van der Meer FJ, Nijhuis MO, Smeets M, de Kleijn DP et al. Matrix metalloproteinase inhibition reduces adventitial thickening and collagen accumulation following balloon dilation. Cardiovasc Res 2002;55:864-869.
45. Cheema AN, Nili N, Li CW, Whittingham HA, Linde J, van Suylen RJ et al. Effects of intravascular cryotherapy on vessel wall repair in a balloon-injured rabbit iliac artery model. Cardiovasc Res 2003;59:222-233. (Pubitemid 36776388)
46. Durante W, Reyna SV, Peyton KJ, Schafer AI. Physiological cyclic stretch directs Larginine transport and metabolism to collagen synthesis in vascular smooth muscle. FASEB J 2000;14:1775-1783.
47. Feldman LJ, Mazighi M, Scheuble A, Deux JF, De Benedetti E, Badier-Commander C et al. Differential expression of matrix metalloproteinases after stent implantation and balloon angioplasty in the hypercholesterolemic rabbit. Circulation 2001;103: 3117-3122. (Pubitemid 32587860)
48. Albini A, Adelmann-Grill BC. Collagenolytic cleavage products of collagen type I as chemoattractants for human dermal fibroblasts. Eur J Cell Biol 1985;36:104-107. (Pubitemid 15165584)
49. Malone JD, Richards M, Jeffrey JJ. Recruitment of peripheral mononuclear cells by mammalian collagenase digests of type I collagen. Matrix 1991;11:289-295.
50. Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 1996;87:1069-1078. (Pubitemid 26427990)
51. Li S, Chow LH, Pickering JG. Cell surface-bound collagenase-1 and focal substrate degradation stimulate the rear release of motile vascular smooth muscle cells. J Biol Chem 2000;275:35384-35392.
52. Kagami S, Kondo S, Loster K, Reutter W, Urushihara M, Kitamura A et al. Collagen type I modulates the platelet-derived growth factor (PDGF) regulation of the growth and expression of beta 1 integrins by rat mesangial cells. Biochem Biophys Res Commun 1998;252:728-732. (Pubitemid 28556844)
53. Jones GT, Tarr GP, Phillips LV, Wilkins GT, van Rij AM, Williams MJ. Active matrix metalloproteinases 3 and 9 are independently associated with coronary artery in-stent restenosis. Atherosclerosis 2009;207:603-607.
54. Nuthakki VK, Fleser PS, Malinska LE, Seymour ML, Callahan RE, Bendick PJ et al. Lysyl oxidase expression in a rat model of arterial balloon injury. J Vasc Surg 2004; 40:123-129. (Pubitemid 38813072)
55. Nwogu JI, Geenen D, Bean M, Brenner MC, Huang X, Buttrick PM. Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation 2001;104:2216-2221. (Pubitemid 33043303)
56. Franklin TJ, Morris WP, Edwards PN, Large MS, Stephenson R. Inhibition of prolyl 4-hydroxylase in vitro and in vivo by members of a novel series of phenanthrolinones. Biochem J 2001;353:333-338. (Pubitemid 32096943)
57. Spears JR, Zhan H, Khurana S, Karvonen RL, Reiser KM. Modulation by beta-aminopropionitrile of vessel luminal narrowing and structural abnormalities in arterial wall collagen in a rabbit model of conventional balloon angioplasty versus laser balloon angioplasty. J Clin Invest 1994;93:1543-1553.
58. Wildgruber M, Weiss W, Berger h, Wolf O, Heider P. Association of circulating transforming growth factor beta, tumor necrosis factor alpha and basic fibroblast growth factor with restenosis after transluminal angioplasty. Eur J Vasc Endovasc Surg 2007;34:35-43. (Pubitemid 46852386)
59. Prud'homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007;87: 1077-1091.
60. Kubota K, Okazaki J, Louie O, Kent KC, Liu B. TGF-beta stimulates collagen I in vascular smooth muscle cells via a short element in the proximal collagen promoter. J Surg Res 2003;109:43-50. (Pubitemid 36263422)
61. Hishikawa K, Oemar BS, Tanner FC, Nakaki T, Fujii T, Luscher TF. Overexpression of connective tissue growth factor gene induces apoptosis in human aortic smooth muscle cells. Circulation 1999;100:2108-2112. (Pubitemid 29532063)
62. Yamamoto K, Morishita R, Tomita N, Shimozato T, Nakagami H, Kikuchi A et al. Ribozyme oligonucleotides against transforming growth factor-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease. Circulation 2000;102:1308-1314.
63. Merrilees M, Beaumont B, Scott L, Hermanutz V, Fennessy P. Effect of TGF-beta(1) antisense S-oligonucleotide on synthesis and accumulation of matrix proteoglycans in balloon catheter-injured neointima of rabbit carotid arteries. J Vasc Res 2000;37: 50-60. (Pubitemid 30158041)
64. Ryan ST, Koteliansky VE, Gotwals PJ, Lindner V. Transforming growth factor-beta-dependent events in vascular remodeling following arterial injury. J Vasc Res 2003;40:37-46. (Pubitemid 36351194)
65. Kingston PA, Sinha S, Appleby CE, David A, Verakis T, Castro MG et al. Adenovirusmediated gene transfer of transforming growth factor-beta 3, but not transforming growth factor-beta 1, inhibits constrictive remodeling and reduces luminal loss after coronary angioplasty. Circulation 2003;108:2819-2825. (Pubitemid 37498986)
66. Ghosh J, Baguneid M, Khwaja N, Murphy MO, Turner N, Halka A et al. Reduction of myointimal hyperplasia after arterial anastomosis by local injection of transforming growth factor beta3. J Vasc Surg 2006;43:142-149. (Pubitemid 43083522)
67. Korpal M, Kang Y. Targeting the transforming growth factor-beta signalling pathway in metastatic cancer. Eur J Cancer 2010;46:1232-1240.
68. Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009;5:200-206.
69. Yao EH, Fukuda N, Ueno T, Matsuda H, Nagase H, Matsumoto Y et al. A pyrrole-imidazole polyamide targeting transforming growth factor-beta1 inhibits restenosis and preserves endothelialization in the injured artery. Cardiovasc Res 2009;81:797-804.
70. Tian M, Neil JR, Schiemann WP. Transforming growth factor-b and the hallmarks of cancer. Cell Signal 2010 Nov 6. [Epub ahead of print].
71. Sawyer JS, Beight DW, Britt KS, Anderson BD, Campbell RM, Goodson T Jr, Herron DK, Li HY, McMillen WT, Mort N, Parsons S, Smith EC, Wagner JR, Yan L, Zhang F, Yingling JM. Synthesis and activity of new aryl- and heteroarylsubstituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Bioorg Med Chem Lett 2004;14: 3581-3584. (Pubitemid 38737172)
72. Tojo M, Hamashima Y, Hanyu A, Kajimoto T, Saitoh M, Miyazono K et al. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci 2005;96:791-800. (Pubitemid 43019830)
73. Moon JA, Kim HT, Cho IS, Sheen YY, Kim DK. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int 2006;70:1234-1243. (Pubitemid 44435174)
74. Kusama H, Kikuchi S, Tazawa S, Katsuno K, Baba Y, Zhai YL et al. Tranilast inhibits the proliferation of human coronary smooth muscle cell through the activation of p21waf1. Atherosclerosis 1999;143:307-313. (Pubitemid 29166911)
75. Watanabe S, Matsuda A, Suzuki Y, Kondo K, Ikeda Y, Hashimoto H et al. Inhibitory mechanism of tranilast in human coronary artery smooth muscle cells proliferation, due to blockade of PDGF-BB-receptors. Br J Pharmacol 2000;130:307-314. (Pubitemid 30261040)
76. Ishiwata S, Verheye S, Robinson KA, Salame MY, de Leon H, King SB IIIet al. Inhibition of neointima formation by tranilast in pig coronary arteries after balloon angioplasty and stent implantation. J Am Coll Cardiol 2000;35:1331-1337. (Pubitemid 30206909)
77. Ward MR, Agrotis A, Kanellakis P, Hall J, Jennings G, Bobik A. Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting. Arterioscler Thromb Vasc Biol 2002;22:940-948. (Pubitemid 34655221)
78. Holmes DR Jr, Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P et al. Circulation. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2002;106:1243-1250. (Pubitemid 34988643)
79. Joner M, Farb A, Cheng Q, Finn AV, Acampado E, Burke AP et al. Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. Arterioscler Thromb Vasc Biol 2007;27:182-189. (Pubitemid 46360397)
80. Ruiz E, Redondo S, Gordillo-Moscoso A, Tejerina T. Pioglitazone induces apoptosis in human vascular smooth muscle cells from diabetic patients involving the transforming growth factor-beta/activin receptor-like kinase-4/5/7/Smad2 signaling pathway. J Pharmacol Exp Ther 2007;321:431-438. (Pubitemid 46624500)
81. Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, Mori Y et al. Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J 2009;23:2968-2977.
82. Chen CC, Lau LF. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 2009;41:771-783.
83. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 2010;106: 1675-1680.
84. Moussad EE, Brigstock DR. Connective tissue growth factor: what's in a name? Mol Genet Metab 2000;71:276-292.
85. Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA. Connective tissue growth factor and cardiac fibrosis. Acta Physiol (Oxf) 2009;195: 321-338.
86. Li G, Xie Q, Shi Y, Li D, Zhang M, Jiang S et al. Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med 2006;8:889-900. (Pubitemid 44097143)
87. Gressner OA, Lahme B, Siluschek M, Gressner AM. Identification of paraxanthine as the most potent caffeine-derived inhibitor of connective tissue growth factor expression in liver parenchymal cells. Liver Int 2009;29:886-897.
88. Xiao R, Liu FY, Luo JY, Yang XJ, Wen HQ, Su YW et al. Effect of small interfering RNA on the expression of connective tissue growth factor and type I and III collagen in skin fibroblasts of patients with systemic sclerosis. Br J Dermatol 2006;155: 1145-1153. (Pubitemid 44729987)
89. Gao RP, Brigstock DR. Connective tissue growth factor hammerhead ribozyme attenuates human hepatic stellate cell function. World J Gastroenterol 2009;15: 3807-3813.
90. Adler SG, Schwartz S, Williams ME, Arauz-Pacheco C, Bolton WK, Lee T et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 2010;5:1420-1428.
91. Rosenbloom J, Castro SV, Jimenez SA. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med 2010;152:159-166.
92. Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem 2007;101:9-33. (Pubitemid 46652569)
93. Vittal R, Zhang H, Han MK, Moore BB, Horowitz JC, Thannickal VJ. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. J Pharmacol Exp Ther 2007;321:35-44. (Pubitemid 46456971)
94. Jacob T, Ascher E, Alapat D, Olevskaia Y, Hingorani A. Activation of p38MAPK signaling cascade in a VSMC injury model: role of p38MAPK inhibitors in limiting VSMC proliferation. Eur J Vasc Endovasc Surg 2005;29:470-478. (Pubitemid 40973841)
95. Leppanen O, Janjic N, Carlsson MA, Pietras K, Levin M, Vargeese C et al. Intimal hyperplasia recurs after removal of PDGF-AB and -BB inhibition in the rat carotid artery injury model. Arterioscler Thromb Vasc Biol 2000;20:E89-E95.
96. Hollenbeck St, Itoh H, Louie O, Faries PL, Liu B, Kent KC. Type I collagen synergistically enhances PDGF-induced smooth muscle cell proliferation through pp60src-dependent crosstalk between the alpha2beta1 integrin and PDGFbeta receptor. Biochem Ciophys Res Commun 2004;325:328-337. (Pubitemid 39441197)
97. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991;253:1129-1132. (Pubitemid 21917260)
98. Yamasaki Y, Miyoshi K, Oda N, Watanabe M, Miyake H, Chan J et al. Weekly dosing with the platelet-derived growth factor receptor tyrosine kinase inhibitor SU9518 significantly inhibits arterial stenosis. Circ Res 2001;88:630-636. (Pubitemid 32275800)
99. Hart CE, Kraiss LW, Vergel S, Gilbertson D, Kenagy R, Kirkman T et al. PDGF beta receptor blockade inhibits intimal hyperplasia in the baboon. Circulation 1999;99: 564-569. (Pubitemid 29061874)
100. Banai S, Gertz SD, Gavish L, Chorny M, Perez LS, Lazarovichi G et al. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. Cardiovasc Res 2004;64:165-171. (Pubitemid 39208933)
101. Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol 2006;69:1527-1533.
102. Cheema AN, Hong T, Nili N, Segev A, Moffat JG, Lipson KE et al. Adventitial microvessel formation after coronary stenting and the effects of SU11218, a tyrosine kinase inhibitor. J Am Coll Cardiol 2006;47:1067-1075.
103. Liu Y, Dolence J, Ren J, Rao M, Sreejayan N. Inhibitory effect of dehydrozingerone on vascular smooth muscle cell function. J Cardiovasc Pharmacol 2008;52:422-429.
104. Vallières K, Petitclerc E, Laroche G. On the ability of imatinib mesylate to inhibit smooth muscle cell proliferation without delaying endothelialization: an in vitro study. Vascul Pharmacol 2009;51:50-56.
105. Kimura S, Egashira K, Nakano K, Iwata E, Miyagawa M, Tsujimoto H et al. Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation. Circulation 2008;118:S65-S70.
106. Serruys PW, Heyndrickx GR, Patel J, Cummins PA, Kleijne JA, Clowes AW. Effect of an anti-PDGF-beta-receptor-blocking antibody on restenosis in patients undergoing elective stent placement. Int J Cardiovasc Intervent 2003;5:214-222. (Pubitemid 38004880)
107. Zymek P, Bujak M, Chatila K, Cieslak A, Thakker G, Entman ML et al. The role of platelet-derived growth factor signaling in healing myocardial infarcts. J Am Coll Cardiol 2006;48:2315-2323. (Pubitemid 44855440)
108. Schonherr E, Hausser H, Beavan L, Kresse H. Decorin-type I collagen interaction. Presence of separate core protein-binding domains. J Biol Chem 1995;270: 8877-8883.
109. Ferdous Z, Wei VM, Iozzo R, Höök M, Grande-Allen KJ. Decorin-transforming growth factor- interaction regulates matrix organization and mechanical characteristics of three-dimensional collagen matrices. J Biol Chem 2007;282:35887-35898. (Pubitemid 350277129)
110. Nili N, Cheema AN, Giordano FJ, Barolet AW, Babaei S, Hickey R et al. Decorin inhibition of PDGF-stimulated vascular smooth muscle cell function: potential mechanism for inhibition of intimal hyperplasia after balloon angioplasty. Am J Pathol 2003; 163:869-878. (Pubitemid 37040123)
111. Al Haj Zen A, Lafont A, Durand E, Brasselet C, Lemarchand P, Godeau G et al. Effect of adenovirus-mediated overexpression of decorin on metalloproteinases, tissue inhibitors of metalloproteinases and cytokines secretion by human gingival fibroblasts. Matrix Biol 2003;22:251-258. (Pubitemid 36802367)
112. Yan W, Wang P, Zhao CX, Tang J, Xiao X, Wang DW. Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor-beta/smad and p38 mitogen-activated protein kinase signaling pathways. Hum Gene Ther 2009;20:1190-1200.
113. Ranjzad P, Salem HK, Kingston PA. Adenovirus-mediated gene transfer of fibromodulin inhibits neointimal hyperplasia in an organ culture model of human saphenous vein graft disease. Gene Ther 2009;16:1154-1162.
114. Hu Y, Sun H, Owens RT,Wu J, Chen YQ, Berquin IM et al. Tor and androgen receptor pathways. Neoplasia 2009;11:1042-1053.
115. Rizvi MA, Katwa L, Spadone DP, Myers PR. The effects of endothelin-1 on collagen type I and type III synthesis in cultured porcine coronary artery vascular smooth muscle cells. J Mol Cell Cardiol 1996;28:243-252. (Pubitemid 26110469)
116. Barolet AW, Babaei S, Robinson R, Picard P, Tsui W, Nili N et al. Administration of exogenous endothelin-1 following vascular balloon injury: early and late effects on intimal hyperplasia. Cardiovasc Res 2001;52:468-476. (Pubitemid 33153110)
117. Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H. Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 1995;44:895-899.
118. Reel B, Oktay G, Ozkal S, Islekel H, Ozer E, Ozsarlak-Sozer G et al. MMP-2 and MMP-9 Alteration in Response to Collaring in Rabbits: The Effects of Endothelin Receptor Antagonism. J Cardiovasc Pharmacol Ther 2009;14:292-301.
119. Kirchengast M. Endothelin receptor blockade and in-stent restenosis. J Cardiovasc Pharmacol 2001;38:S31-S34.
120. Huckle WR, Drag MD, Acker WR, Powers M, McFall RC, Holder DJ et al. Effects of L-749,329, an ET(A)/ET(B) endothelin receptor antagonist, in a porcine coronary artery injury model of vascular restenosis. Circulation 2001;103:1899-1905. (Pubitemid 32328405)
121. Kitada K, Yui N, Matsumoto C, Mori T, Ohkita M, Matsumura Y. Inhibition of endothelin ETB receptor system aggravates neointimal hyperplasia after balloon injury of rat carotid artery. J Pharmacol Exp Ther 2009;331:998-1004.
122. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992;71:503-510.
123. Rombouts K, Wielant A, Hellemans K, Schuppan D, Geerts A. Influence of aldosterone on collagen synthesis and proliferation of rat cardiac fibroblasts. Br J Pharmacol 2001;134:224-232. (Pubitemid 32835486)
124. Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997;17:1152-1156. (Pubitemid 27260336)
125. Van Belle E, Bauters C, Wernert N, Hamon M, McFadden EP, Racadot A et al. Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist. Cardiovasc Res 1995;29: 27-32.
126. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001;104:467-472. (Pubitemid 32678279)
127. Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US. Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 1994;19:125-134. (Pubitemid 24060187)
128. Srivatsa SS, Fitzpatrick LA, Tsao PW, Reilly TM, Holmes DR Jr, Schwartz RS et al. Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation. Cardiovasc Res 1997;36:408-428. (Pubitemid 28037364)
129. Urbahns K, Härter M, Albers M, Schmidt D, Stelte-Ludwig B, Brüggemeier U et al. Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides. Bioorg Med Chem Lett 2007;17:6151-6154. (Pubitemid 47552838)
130. Margolin L, Fishbein I, Banai S, Golomb G, Reich R, Perez LS et al. Metalloproteinase inhibitor attenuates neointima formation and constrictive remodeling after angioplasty in rats: augmentative effect of alpha(v)beta(3) receptor blockade. Atherosclerosis 2002;163:269-277. (Pubitemid 34615817)
131. Varadarajulu J, Laser M, Hupp M, Wu R, Hauck CR. Targeting of alpha(v) integrins interferes with FAK activation and smooth muscle cell migration and invasion. Biochem Biophys Res Commun 2005;331:404-412. (Pubitemid 40602652)
132. Kappert K, Furundzija V, Fritzsche J, Margeta C, Krüger J, Meyborg H et al. Integrin cleavage regulates bidirectional signalling in vascular smooth muscle cells. Thromb Haemost 2010;103:556-563.
133. Liu YN, Pan SL, Peng CY, Guh JH, Huang DM, Chang YL et al. YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9. J Pharmacol Exp Ther 2006; 316:35-41.
134. de Smet BJ, de Kleijn D, Hanemaaijer R, Verheijen JH, Robertus L, van Der Helm YJ et al. Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty: a study in the atherosclerotic Yucatan micropig. Circulation 2000;101:2962-2967. (Pubitemid 30415888)
135. Cherr GS, Motew SJ, Travis JA, Fingerle J, Fisher L, Brandl M et al. Metalloproteinase inhibition and the response to angioplasty and stenting in atherosclerotic primates. Arterioscler Thromb Vasc Biol 2002;22:161-166. (Pubitemid 34076248)
136. van Beusekom HM, Post MJ, Whelan DM, de Smet BJ, Duncker DJ, van der
137. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 1996;78:38-43. (Pubitemid 26004118)
138. Seidah NG, Chretien M. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res 1999;848:45-62. (Pubitemid 30001653)
139. Stawowy P, Meyborg H, Stibenz D, Borges Pereira Stawowy N, Roser M, Thanabalasingam U et al. Furin-like proprotein convertases are central regulators of the membrane type matrix metalloproteinase-pro-matrix metalloproteinase-2 proteolytic cascade in atherosclerosis. Circulation 2005;111:2820-2827. (Pubitemid 40791555)
140. Kappert K, Meyborg H, Baumann B, Furundzija V, Kaufmann J, Graf K et al. Integrin cleavage facilitates cell surface-associated proteolysis required for vascular smooth muscle cell invasion. Int J Biochem Cell Biol 2009;41:1511-1517.
141. Stawowy P, Margeta C, Kallisch H, Seidah NG, Chrétien M, Fleck E et al. Regulation of matrix metalloproteinase MT1-MMP/MMP-2 in cardiac fibroblasts by TGF-beta1 involves furin-convertase. Cardiovasc Res 2004;63:87-97. (Pubitemid 38759813)
142. Sluijter JP, Verloop RE, Pulskens WP, Velema E, Grimbergen JM, Quax PH et al. Involvement of furin-like proprotein convertases in the arterial response to injury. Cardiovasc Res 2005;68:136-143. (Pubitemid 41253564)
143. Jenkins GM, Crow MT, Bilato C, Gluzband Y, Ryu WS, Li Z et al. Increased expression of membrane-type matrix metalloproteinase and preferential localization of matrix metalloproteinase-2 to the neointima of balloon-injured rat carotid arteries. Circulation 1998;97:82-90. (Pubitemid 28036158)
144. Godin D, Ivan E, Johnson C, Magid R, Galis ZS. Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation 2000;102:2861-2866.
145. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008;75:346-359. (Pubitemid 350298459)